Patents by Inventor Pierre Chapdelaine

Pierre Chapdelaine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR-based methods and products for increasing frataxin levels and uses thereof
    Patent number: 10323073
    Abstract: Methods and products (e.g., gRNAs, recombinant fusion proteins, frataxin targeting systems, compositions and kits) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Pierre Chapdelaine, Joël Rousseau
  • Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
    Patent number: 10280419
    Abstract: Methods and products are described related to use of the CRISPR/Cas9 system to introduce a modification into an APP gene, such as guide RNAs and recombinant proteins, for decreasing amyloid beta peptide produced by a cell. Also described are uses of such methods and products for the treatment of Alzheimer's disease and/or age-related cognitive decline in a cell from a subject in need thereof.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: May 7, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Joël Rousseau, Pierre Chapdelaine
  • Methods and products for increasing frataxin levels and uses thereof
    Patent number: 9708414
    Abstract: Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 18, 2017
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Joel Rousseau, Pierre Chapdelaine, Zoe Coulombe
  • METHODS AND PRODUCTS FOR INCREASING FRATAXIN LEVELS AND USES THEREOF
    Publication number: 20140315782
    Abstract: Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Inventors: Jacques P. Tremblay, Joel Rousseau, Pierre Chapdelaine, Zoe Coulombe
  • METHODS FOR THE REGULATION OF THE PROSTAGLANDIN F SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF
    Publication number: 20130324545
    Abstract: AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2?. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2? are also provided.
    Type: Application
    Filed: July 17, 2013
    Publication date: December 5, 2013
    Applicant: UNIVERSITE LAVAL
    Inventors: Michael Fortier, Pierre Chapdelaine, Eva Bresson, Éric Madore
  • Prostaglandin E2 modulation and uses thereof
    Patent number: 8546077
    Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 1, 2013
    Assignee: Université Laval
    Inventors: Jack Puymirat, Daniel Beaulieu, Pierre Chapdelaine
  • METHODS FOR THE REGULATION OF THE PROSTAGLANDIN F SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF
    Publication number: 20110236394
    Abstract: AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2?. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2? are also provided.
    Type: Application
    Filed: November 14, 2008
    Publication date: September 29, 2011
    Applicant: UNIVERSITE LAVAL
    Inventors: Michel Fortier, Pierre Chapdelaine, Eva Bresson, Eric Madore
  • PROSTAGLANDIN E2 MODULATION AND USES THEREOF
    Publication number: 20100304416
    Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
    Type: Application
    Filed: June 16, 2010
    Publication date: December 2, 2010
    Inventors: Jack PUYMIRAT, Daniel Beaulieu, Pierre Chapdelaine
  • PROSTAGLANDIN E2 MODULATION AND USES THEREOF
    Publication number: 20090088400
    Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
    Type: Application
    Filed: September 5, 2008
    Publication date: April 2, 2009
    Inventors: Jack PUYMIRAT, Daniel Beaulieu, Pierre Chapdelaine